Authors : Sharmila G, Praba V
DOI : 10.18231/j.achr.2020.015
Volume : 5
Issue : 1
Year : 2020
Page No : 75-80
Breast cancer has now become the most common cancer among Indian females exceeding cervical
cancer. Age adjusted incidence rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000
women. Trends of breast cancer now in India are increasing incidence at younger age group, late stage
of presentation, aggressive cancers in the young. Bcl 2-a protooncogene identified in 1984. The protein
is found mainly in the periphery of mitochondria, on the perinuclear membrane, and in the endoplasmic
reticulum. In our study bcl2 expression in different histologic types of breast carcinoma and correlates we
read about its expression with other clinico pathologic variables such as tumour size, histological grade,
lymph node status, hormone receptor status and Nottingham prognostic index. :In this study 23.3% (7
out of 30) of the cases showed positivity for bcl2 expression of which all cases were strongly positive.
Bcl2 expression was found in 45.5% grade I well differentiated ductal carcinoma,14.3% of Grade II
Moderately differentiated ductal carcinomas, all cases of mucinous carcinoma of breast(p-<0>
and ER/PR status found to have a statistically significant direct correlation with p value<0>
Bcl2 antagonism in these ER+ tumors might increase the effectiveness of these predominately proapoptotic
treatment even more than it does from combination with endocrine therapies. Further development of bcl2
inhibitors has been explored and small molecule inhibitors such as ABT-737 AND ABT-199 have been
recently introduced. Emerging evidence also suggests the usefulness of this type of theraphy in breast
cancer.
Keywords: Breast, Carcinoma, Bcl2, Apoptosis, BH3mimetics.